Compare HRTG & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HRTG | GHRS |
|---|---|---|
| Founded | 2012 | 2018 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 898.0M | 1.0B |
| IPO Year | 2014 | 2021 |
| Metric | HRTG | GHRS |
|---|---|---|
| Price | $28.64 | $15.04 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 9 |
| Target Price | $33.50 | ★ $40.33 |
| AVG Volume (30 Days) | ★ 344.0K | 189.8K |
| Earning Date | 06-12-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 214.43 | N/A |
| EPS | ★ 6.32 | N/A |
| Revenue | ★ $847,330,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.89 | N/A |
| P/E Ratio | $4.50 | ★ N/A |
| Revenue Growth | ★ 3.71 | N/A |
| 52 Week Low | $13.28 | $7.98 |
| 52 Week High | $31.98 | $19.51 |
| Indicator | HRTG | GHRS |
|---|---|---|
| Relative Strength Index (RSI) | 62.12 | 46.63 |
| Support Level | $25.47 | $12.04 |
| Resistance Level | $29.18 | $16.22 |
| Average True Range (ATR) | 1.27 | 0.96 |
| MACD | 0.16 | -0.07 |
| Stochastic Oscillator | 89.40 | 31.13 |
Heritage Insurance Holdings Inc is a regional property and casualty insurance company that offers a variety of personal and commercial insurance products. Through its subsidiaries, Heritage Property & Casualty Insurance, Narragansett Bay Insurance, and Zephyr Insurance, the company issues personal residential property insurance in various states in the United States. It also offers commercial residential insurance predominantly for its Florida properties. Heritage Insurance manages insurance underwriting, customer services, actuarial analysis, distribution, and claims processing internally. Company operates in Alabama, California, Connecticut, Delaware, Florida, Georgia, Hawaii, Maryland, Massachusetts, Mississippi, New Jersey, New York, North Carolina, Rhode Island, South Carolina.
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.